SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now

EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Clinical Study

The use of medical-grade cannabis in patients non-responders to Nabiximols.

Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB;… ·Journal of the neurological sciences ·2016 ·DOI: 10.1016/j.jns.2016.07.059

Citation

View on PubMed

Evidence Strength

Emerging evidence 37 / 100

Methodology 0/25

Highest-tier methodology assigned to the study.

Sample size 0/25

Sample size not recorded.

Peer review 25/25

Published in a peer-reviewed, PubMed-indexed journal.

Replication / recency 12/25

Published within the last decade.

How is this calculated?

Other studies in this cluster

Neurology

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2017

RCT n=30

Neurology

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015

Neurology

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

Pain medicine (Malden, Mass.) · 2016

RCT

Neurology

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Expert review of pharmacoeconomics & outcomes research · 2016

Neurology

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Journal of clinical pharmacology · 2015

Neurology

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

European neurology · 2016

The use of medical-grade cannabis in patients non-responders to Nabiximols.

Citation

Other studies in this cluster

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

Contact us

Categories

Editions

Business of cannabis

Popular

Time is running out to nominate

Recent Searches

Popular Searches

Recent Searches

Popular Searches

The use of medical-grade cannabis in patients non-responders to Nabiximols.

Citation

Other studies in this cluster

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

Cannabis news, every Monday morning.

Time is running out to nominate